INGREZZA (valbenazine) Patient Assistance Program
Don’t let the high cost of brand specialty VMAT2 inhibitor therapy disrupt your treatment. We help eligible patients access Ingrezza (valbenazine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing — Applying To Neurocrine Directly Is Always Free
- Paperwork, Documentation & Doctor-Coordination Handled For You
- Comprehensive Support: From Application To Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Guidance — The $2,100 Cap Changed The Math For Ingrezza Patients
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Ingrezza (Valbenazine) Is FDA-Approved For Tardive Dyskinesia And Chorea Associated With Huntington’s Disease — One Capsule, Once Daily, With No Titration Required. Ingrezza Sprinkle (Approved 2024) Offers The Same Doses As Granules For Patients With Difficulty Swallowing.
- Without Assistance, Ingrezza’s Cash Price Runs Roughly $7,870–$8,610 Per 30-Capsule Month — Over $94,000 Per Year. Neurocrine’s Patient Assistance Program Provides Ingrezza Free To Patients Who Are Uninsured, Lack Coverage For It, Or Have Qualifying Financial Need.
- Commercially Insured Patients Can Pay As Little As $0 Per Fill Through The Ingrezza Co-Pay Savings Program — And New Patients May Qualify For A 30-Day Free Trial. Neurocrine Reports Roughly 90% Of Patients Pay $10 Or Less.
- For Medicare Patients, The Part D Out-Of-Pocket Cap ($2,100 In 2026) Now Limits Annual Drug Spending — And The HealthWell Foundation Runs A Dedicated Tardive Dyskinesia Medicare Fund. No Generic Exists: Settlements Keep Generics Off The Market Until 2038.
What Is Ingrezza Prescription Assistance Program?
The Ingrezza Patient Assistance Program is run through Neurocrine Access Support (formerly the INBRACE Support Program) and provides Ingrezza at no cost to patients who are uninsured, whose insurance doesn’t cover Ingrezza, or who demonstrate qualifying financial need. Applying directly (1-84-INGREZZA / 1-844-647-3992, Mon–Fri 8 AM–8 PM ET) is always free, and the program pairs patients with benefits investigators and regional access managers. The hard part is what surrounds the application: tardive dyskinesia documentation from your prescriber, insurance benefits verification, specialty-pharmacy coordination, prior-authorization records, denial appeals, and annual renewals — plus choosing correctly among the free-trial, copay-card, foundation-fund, and free-drug routes, which serve different insurance situations. For a flat $69.95 per month, our Patient Advocates handle every step and route you to the right program the first time.
Pharmacy Price Comparison
- Without assistance, Ingrezza costs roughly $8,500–$10,500/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$10,200 | Save ~$10,130/mo |
| CVS Pharmacy | ~$10,500 | Save ~$10,430/mo |
| Walmart | ~$9,000 | Save ~$8,930/mo |
| Costco | ~$8,800 | Save ~$8,730/mo |
Specialty Pharmacy | ~$9,200 | Save ~$9,130/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Ingrezza Prescription Program?
Neurocrine’s assistance programs are free to apply for and provide Ingrezza at no medication cost if approved. Our $69.95/month service covers full advocacy — for patients who want an experienced team managing the process end-to-end, especially across the trial → copay → PAP sequence.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Ingrezza:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $8,500–$10,500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Neurocrine Access Support reviews eligibility based on insurance status and financial need. You will generally qualify if the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Ingrezza assistance:
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Ingrezza Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Your Insurance Doesn’t Cover Ingrezza, Or You Have Qualifying Financial Need
- You Can Provide Income Documentation For The Program’s Financial Review
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Ingrezza:
Ingrezza (valbenazine) is a selective VMAT2 inhibitor — it modulates dopamine signaling in the brain regions that control movement, treating the involuntary movements of tardive dyskinesia and Huntington’s disease chorea without treating (or interfering with) the underlying psychiatric medication that may have caused them.
How Ingrezza Works:
Tardive dyskinesia arises after long-term use of dopamine-blocking medications (antipsychotics, some anti-nausea drugs), which leave movement circuits hypersensitive to dopamine. Valbenazine inhibits VMAT2, the transporter that loads dopamine into nerve-signal packets, smoothing out the excess signaling that drives involuntary movements. Critically, patients typically stay on their psychiatric medication — Ingrezza treats the movement disorder alongside it, which is why coordination between psychiatrist, neurologist, and pharmacy matters.
Form and Use:
One capsule, once daily — starting at 40 mg and typically increasing to 80 mg, with no complex titration schedule. Ingrezza Sprinkle, approved in 2024, offers the same strengths as granules that can be sprinkled on soft food for patients with swallowing difficulties — common in the populations this drug serves. Improvement in involuntary movements is typically assessed over 6–8 weeks, and consistent daily dosing is what sustains it.
Generic Availability:
There is no generic valbenazine, and none is coming soon: Neurocrine’s patent settlements license generic entry beginning March 2038. That is one of the longest generic horizons of any major specialty drug — which makes the assistance programs on this page not a stopgap but the long-term affordability plan for most patients.
Warnings:
Ingrezza can cause somnolence — don’t drive until you know how it affects you — and QT-interval prolongation in patients on certain other medications or with heart rhythm conditions. Depression and suicidal thoughts have been reported in Huntington’s disease patients. Tell your prescriber about all medications (strong CYP3A4 inhibitors and MAOIs interact)
FAQ (Frequently Asked Questions)
How Much Does Ingrezza Cost Without Insurance?
Cash prices run roughly $7,870–$8,610 per 30-capsule month depending on strength — over $94,000 per year. Eligible patients can receive Ingrezza free through Neurocrine’s Patient Assistance Program; our $69.95 monthly fee covers full advocacy and enrollment management
What Is Tardive Dyskinesia?
Tardive dyskinesia (TD) is a movement disorder — repetitive, involuntary movements often of the face, tongue, or limbs — that can develop after long-term use of dopamine-blocking medications like antipsychotics. It affects an estimated 500,000+ people in the U.S., many undiagnosed. Ingrezza was the first FDA-approved treatment for it.
Does Medicare Cover Ingrezza?
Yes — under Part D. Since the Part D redesign, your total annual out-of-pocket for all covered drugs is capped ($2,100 in 2026), payments can be spread monthly, and the HealthWell Foundation runs a dedicated Tardive Dyskinesia Medicare Access fund for cost-sharing help. Manufacturer copay cards, however, cannot be used with Medicare.
Is There A Free Trial?
Yes — eligible new patients can receive a 30-day free trial through Neurocrine Access Support, not contingent on purchase. It’s a genuinely useful bridge while insurance authorization or assistance applications process — we time the paperwork so coverage is ready when the trial ends.
Is There A Generic For Ingrezza
No — and patent settlements keep generics off the U.S. market until March 2038. The alternative VMAT2 inhibitor, Austedo (deutetrabenazine), is a different drug with different dosing, not a generic substitute.
What About Ingrezza Sprinkle?
? Same drug, same strengths, in granule form for patients who can’t swallow capsules — sprinkled on soft food. Approved in 2024. The same assistance programs apply; if swallowing is a barrier for you or the patient you care for, ask your prescriber about switching forms, not stopping
What If My Application Is Denied?
If denied, we explore alternatives — switching to Austedo (with its own PAP), generic tetrabenazine for Huntington’s chorea (much cheaper but more side effects), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the National Alliance on Mental Illness (NAMI), Huntington’s Disease Society of America, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
Between Neurocrine’s free-drug program, the $0 copay card, the 30-day trial, the HealthWell Medicare fund, and the $2,100 Part D cap, nearly every Ingrezza patient has a path to affordable treatment — the challenge is sequencing them correctly. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.